Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Caplin Point Laboratories Ltd

    The genesis of Caplin Point took place in the year 1990 as a Private Limited company mainly to manufacture a wide range of Ointments, Creams and other External applications in a

  • No Image
    Celestial Biolabs Ltd

    Celestial Biolabs Ltd CBL) is Hyderabad based bio pharma company. The company has bought about 6 acres of land from APIIC near biotech Park for manufacturing biopharmaceutical

  • No Image
    Ceva Polchem Pvt Ltd

    Ceva Polchem started its operations in the year 2002. Its state-of-the-art plant was located outside Pune. It also houses its R&D cum Technical Services Laboratory. With 270

  • No Image
    Cipla Ltd

    Incorporated in 1935, Cipla Limited (CIPLA) has a diverse range of more than 1,000 products and 180 global partners across 120 countries. Cipla has a presence in Africa, Middle